K2M shareholder sells $10M in stock — 5 things to know

K2M’s major shareholder Carson Andrew & Stow Welsh sold $10,560,821 in stock in a transaction that occurred Friday, July 17, according to WKRB.

Advertisement

Here are five notes:

 

1. The shareholder sold 467,293 shares of the stock.

 

2. Each share sold at an average price of $22.60.

 

3. K2M, a global medical device company, presently has a consensus rating of “Buy” and a price target of $28.75.

 

4. K2M shares have a 50-day moving average of $24.27 and a 200-day moving average of $22.29.

 

5. The company’s market cap is approximately $958 million.

 

More on devices:
Stryker moves to dismisses lawsuit involving Accolade hip replacement system — 4 quick facts
Bone grafts market growing globally: 5 things to know
4 notes on new FDA-approved prosthesis for amputations

 

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new technology acquisitions to regulatory clearances to leadership changes, here are 20 developments and updates from the biggest players…

  • SurGenTec’s ION-C earned FDA 510(k) clearance for ION-C navigation instruments with the ION-C posterior cervical facet fixation implant, according to…

  • VB Spine has made big pushes into the spine medtech space so far in 2026, including global expansions. Six headlines…

Advertisement

Comments are closed.